成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

替馬考昔,Tilmacoxib
  • 替馬考昔,Tilmacoxib

替馬考昔|T15630|TargetMol

價(jià)格 17500 10600 13800
包裝 100mg 25mg 50mg
最小起訂量 1mg
發(fā)貨地 上海
更新日期 2024-12-12
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:替馬考昔英文名稱:Tilmacoxib
CAS:180200-68-4品牌: TargetMol
產(chǎn)地: 美國(guó)保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號(hào): T15630
2024-12-12 替馬考昔 Tilmacoxib 100mg/17500RMB;25mg/10600RMB;50mg/13800RMB 17500 TargetMol 美國(guó) Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. 抑制劑

Product Introduction

Bioactivity

名稱Tilmacoxib
描述Tilmacoxib is a highly selective, time-dependent, and irreversible inhibitor of human COX-2 ( IC50: 85 nM in an enzyme assay).
體外活性Tilmacoxib is less potent at inhibiting calcium ionophore-induced thromboxane B2 production in washed human platelets (COX-1) (IC50=6.21 μM). Tilmacoxib inhibits yeast-expressed human recombinant COX-2 (IC50: 0.085 μM), in an enzyme assay. Tilmacoxib does not inhibit human COX-1 prepared from human platelets at concentrations up to 100 μM. Tilmacoxib diminishes lipopolysaccharide-induced prostaglandin E2 production in human peripheral blood mononuclear cells (COX-2) (IC50=15.1 nM), in a cell-based assay. Tilmacoxib displays highly selective inhibition of human COX-2, and its activity is more selective than that of other COX-2 inhibitors (NS-398 and SC-58635). Human recombinant COX-2 activity is attenuated by Tilmacoxib in a dose-dependent and time-dependent manner[1]. Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, Tilmacoxib (JTE522), is also mediated by a PGE2-independent pathway Combination of Tilmacoxib and Arachidonic acid results in marked retardation of wound healing compared to the control, but Tilmacoxib does not completely suppress the increase in cellular PGE2 content following the addition of arachidonate[2].
體內(nèi)活性Administration of Tilmacoxib (10 mg/kg) obviously inhibits ACF formation with a 30% reduction in total ACF/colon (p<0.01). The data on crypt multiplicity display that 10 mg/kg Tilmacoxib significantly decreases the formation of foci containing 1-3 crypts but not foci containing four crypts or more. Administration of the low dose of Tilmacoxib (3 mg/kg) has no inhibitory effects on either the total ACF or crypt multiplicity. From the start of the experiment, a total of 80 male F344 rats are treated with 3 or 10 mg/kg of body weight Tilmacoxib or vehicle by oral gavage five times weekly. One week later, rats receive s.c. injections of saline or 20 mg/kg of body weight DMH once weekly for four successive weeks. At the end of 12 weeks after the start of the experiment, all rats are sacrificed and colons are evaluated for ACF. 10 mg/kg Tilmacoxib significantly suppresses the total ACF/colon. No inhibitory effect is observed in the 3 mg/kg Tilmacoxib treatment group [3].
存儲(chǔ)條件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
關(guān)鍵字Tilmacoxib | JTP-19605 | JTP 19605 | RWJ-57504 | RWJ 57504 | JTE 522 | JTE-522
相關(guān)產(chǎn)品Trometamol | Revaprazan hydrochloride | Ibuprofen | Paradol | Glafenine | Acetaminophen | Indomethacin sodium hydrate | Diclofenac Potassium | Salicylamide | Diclofenac sodium
關(guān)鍵字: RWJ57504|||JTP19605|||替馬考昔|||JTE522|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓,致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū),已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù),以及多種類型的生化試劑產(chǎn)品,包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等,此外,我們還建設(shè)有CADD(計(jì)算機(jī)輔助藥物設(shè)計(jì))研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心,全方位滿足客戶的定制需求。 憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持,我們將有效幫助您縮短研發(fā)周期,取得更成功的結(jié)果。
成立日期 2013-04-18 (12年) 注冊(cè)資本 566.265100萬(wàn)人民幣
員工人數(shù) 100-500人 年?duì)I業(yè)額 ¥ 1億以上
主營(yíng)行業(yè) 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) 經(jīng)營(yíng)模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • TargetMol中國(guó)(陶術(shù)生物)
VIP 3年
  • 公司成立:12年
  • 注冊(cè)資本:566.265100萬(wàn)人民幣
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
  • 公司地址:靜安區(qū)江場(chǎng)三路238號(hào)8樓
詢盤

替馬考昔|T15630|TargetMol相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
VIP2年
陜西締都新材料有限公司
2024-12-18
詢價(jià)
VIP9年
武漢維斯?fàn)柭锕こ逃邢薰?/div>
2024-12-25
¥1295
VIP3年
湖北魏氏化學(xué)試劑股份有限公司
2024-12-20
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的